Beam Therapeutics (BEAM) Study result summary
Event summary combining transcript, slides, and related documents.
Study result summary
27 Oct, 2026BEAM-301 study design
Open-label Phase I/II single-dose IV study in GSD1a patients with R83C; six treated (three each at 20 mg and 40 mg); median follow-up 7.6 months (range 1.9–16.6) at the Aug. 17, 2026 cutoff.
The 60 mg cohort is enrolling 3–6 patients to assess safety, fasting tolerance and changes in starch supplementation.
BEAM-301 clinical findings
Median time to fasting hypoglycemia rose from 2.9 to 4.3 hours at Day 36 in the 20 mg cohort, and from 2.5 to 15.0 hours in the 40 mg cohort.
At 40 mg, 2 of 3 patients reached the 15-hour maximum controlled fast, with glucose generally remaining in the euglycemic range.
Two of 3 patients at 40 mg stopped starch supplementation at their latest assessments; CGM showed more time euglycemic and less hyperglycemic despite reduced starch, with no overall increase in hypoglycemia time.
The 40 mg nonresponder had BMI above 50; lower liver exposure from fixed dosing and compound heterozygosity were proposed as possible factors.
Findings were described as clinical proof of concept for single-dose correction intended to restore endogenous glucose production.
Safety and dose evaluation
Safety was described as acceptable and consistent with IV LNP risks; no dose-limiting toxicities, treatment-related discontinuations or Grade 4/5 treatment-emergent adverse events were reported.
Four of six patients had serious treatment-related adverse events, including three Grade 3 infusion reactions; diarrhea and rhabdomyolysis also resolved.
Infusion-related reactions and transient transaminase elevations were most frequent; liver enzyme elevations resolved without treatment, with all but one Grade 2 AST elevation classified as Grade 1.
Steroid premedication and infusion regimens were modified after Grade 3 infusion reactions; investigators supported escalation to 60 mg.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update